Duffy, Kevin J.,Shaw, Antony,Miller, William,Myers, Andrea,Zimmermann, Michael
申请号：
ES14196983
公开号：
ES2614355T3
申请日:
2008.01.11
申请国别(地区):
ES
年份:
2017
代理人:
摘要：
A compound selected from: N - {[2 - [(4-Bromo-2-fluorophenyl) methyl] -5-hydroxy-6- (1-methylethyl) -3-oxo-2,3-dihydro-4-pyridazinyl] carbonyl} glycine, of formula (Ib) ** Formula ** N - {[2 - [(3,4'-Difluoro-4-biphenylyl) methyl] -5-hydroxy-6- (1-methylethyl) -3- oxo-2,3-dihydro-4-pyridazinyl] carbonyl} glycine, of formula (Ic) ** Formula ** and N - {[2 - {[2-Fluoro-4- (trifluoromethyl) phenyl] methyl} -5 -hydroxy-6- (1-methylethyl) -3-oxo-10 2,3-dihydro-4-pyridazinyl] carbonyl} glycine, of formula (Id) ** Formula ** or a pharmaceutically acceptable salt thereof.Un compuesto seleccionado de: N-{[2-[(4-Bromo-2-fluorofenil)metil]-5-hidroxi-6-(1-metiletil)-3-oxo-2,3-dihidro-4-piridazinil]carbonil}glicina, de fórmula (Ib)**Fórmula** N-{[2-[(3,4'-Difluoro-4-bifenilil)metil]-5-hidroxi-6-(1-metiletil)-3-oxo-2,3-dihidro-4-piridazinil]carbonil}glicina, de fórmula (Ic)**Fórmula** y N-{[2-{[2-Fluoro-4-(trifluorometil)fenil]metil}-5-hidroxi-6-(1-metiletil)-3-oxo-10 2,3-dihidro-4-piridazinil]carbonil}glicina, de fórmula (Id)**Fórmula** o una de sus sales farmacéuticamente aceptables.
